(NASDAQ: GLMD) Galmed Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.
Galmed Pharmaceuticals's earnings in 2025 is -$8,722,000.On average, 3 Wall Street analysts forecast GLMD's earnings for 2025 to be -$17,633,702, with the lowest GLMD earnings forecast at -$16,942,184, and the highest GLMD earnings forecast at -$18,152,340. On average, 3 Wall Street analysts forecast GLMD's earnings for 2026 to be -$4,597,744, with the lowest GLMD earnings forecast at -$4,417,441, and the highest GLMD earnings forecast at -$4,732,972.
In 2027, GLMD is forecast to generate -$2,650,464 in earnings, with the lowest earnings forecast at -$2,546,525 and the highest earnings forecast at -$2,728,419.